Recently, the class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors has drawn interest during the search for efficacious management of ACS, in addition to being used for type 2 diabetic mellitus (T2DM) [5]. Here, SLC5A2 is linked to type 2 diabetes mellitus.